Lundbeck gets FDA-accept and million-dollar milestone payment
The FDA has accepted the Danish company’s registration application for its anti-depressant vortioxetin. The accept also triggers a milestone payment from a Japanese business partner.
by Stefan Singh Kailay
Last week FDA accepted Lundbeck’s registration application for the anti-depressant vortioxetin, and Brintellix was announced as the suggested global brand.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
New drugs to the rescue for Lundbeck
For abonnenter
Canada lures Novo and Lundbeck
For abonnenter
Lundbeck cancels Alzheimer’s drug
For abonnenter
